Home › Compare › MAGTF vs ABBV
MAGTF yields 6.27% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, MAGTF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MAGTF + ABBV for your $10,000?
Magnet Forensics Inc., together with its subsidiaries, engages in the development of data analytics software used for digital forensics investigations to public sector and private enterprises in Canada, the United States, Australia, and Europe. It offers Magnet AXIOM, a digital investigations platform to recover analyze, and report on digital evidence from smartphones, cloud services, IoT devices, and third-party images; Magnet AXIOM CYBER, a digital forensics and incident response solution for businesses that need to perform remote acquisitions, and collect and analyze evidence from computers, cloud, and mobile devices; and Magnet OUTRIDER, a digital evidence triage tool used at crime scenes to scan digital media for the presence of CSAM. The company also provides Magnet AUTOMATE, an orchestration and automation tool to enable law enforcement agencies to create automated and repeatable digital evidence processing workflows; Magnet REVIEW to securely share the digital evidence via a single web-based platform; Magnet ATLAS, a workflow orchestration tool to manage cases, generate real-time reports, and track digital investigations; Magnet Digital Investigation Suite that transform digital investigations with analytics and collaborate agency-wide, securely, and at scale; and Magnet IGNITE, a cloud-based early case assessment triage tool. It serves large government agencies, corporations, and professional services firms. The company was formerly known as JADsoftware Inc. and changed its name to Magnet Forensics Inc. in August 2012. Magnet Forensics Inc. was incorporated in 2010 and is headquartered in Waterloo, Canada.
Full MAGTF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.